Sonata Therapeutics
Volker Herrmann, MD, currently serves as the CEO of Sonata Therapeutics and CEO Partner at Flagship Pioneering, a role held since August 2020. Prior experience includes serving as the Chief Operating Officer at SQZ Biotechnologies and Selenity Therapeutics, as well as the Chief Commercial Officer at Viamet Pharmaceuticals. Herrmann held various leadership positions at Pfizer from 1999 to 2015, culminating as Head of Global Commercial Development, Global Marketing & Global Strategy for Pfizer Vaccines. Academically, Herrmann earned a Doctor of Medicine degree in Cardiology and a PhD in Pharmacology from the University of Freiburg, alongside an MBA from the University of San Diego and a Doctor of Medicine degree from the University of Michigan.
Sonata Therapeutics
Sonata Therapeutics is a new, Boston-based Flagship Pioneering company revolutionizing the world’s understanding of the cellular microenvironment and its importance to human biology and disease. Our product-platform creates drugs based on a systematic, comprehensive characterization of the microenvironment in diseases with high unmet medical need. Through our pioneering science, we identify new targets for therapeutics that induce the release of a programmed diversity of signals with the potential for significant patient impact. Our employees are exceptionally passionate, accountable, collaborative, and innovative. Sonata Therapeutics was founded by Flagship Pioneering, an organization dedicated to the origination and development of first-in-category life sciences companies. Since 2000, Flagship has originated and fostered the development of nearly 100 scientific ventures resulting in $20+ billion in aggregate value, 500+ issued patents, and more than 50 clinical trials for novel therapeutic agents.